<DOC>
	<DOCNO>NCT01114269</DOCNO>
	<brief_summary>This prospective , multi-center cohort study patient history coronary artery disease ( CAD ) documentation either prior myocardial infarction ( MI ) mild moderate leave ventricular dysfunction ( LVEF 35-50 % ) . The primary objective study determine whether biologic marker ECGs utilize advance SCD risk prediction patient CHD LVEF &gt; 30-35 % . The overarch goal study identify series marker alone combination specifically predict risk arrhythmic death compare cause mortality among risk population coronary heart disease ( CHD ) patient preserve leave ventricular ejection fraction ( LVEF &gt; 30-35 % ) . If biologic ECG marker identify specifically predict risk ventricular arrhythmia , marker may serve relatively inexpensive method identify risk . The public health impact identify marker could quite substantial , leading efficient utilization ICDs advance understanding mechanism underlie SCD .</brief_summary>
	<brief_title>PRE-DETERMINE Cohort Study</brief_title>
	<detailed_description>The PRE-DETERMINE Study prospective , multi-center study patient history coronary artery disease ( CAD ) documentation either prior myocardial infarction ( MI ) mild moderate leave ventricular dysfunction ( LVEF 35-50 % ) . Patients enrol 136 site information baseline demographic , clinical characteristic , pertinent past medical history , lifestyle habit , cardiac test result , medication collect via electronic data capture . Electrocardiograms along blood sample also collect baseline , send central laboratory , store future analysis . Contrast-enhanced magnetic resonance imaging ( CE-MRI ) scan collected subset patient analyze . Enrollment close November 2013 patient follow centrally Clinical Coordinating Center via mail/phone document interim non-fatal arrhythmic event cause-specific mortality . Questionnaires inquire intervene ICD implantation , ICD therapy , cardiac arrest , pertinent cardiovascular endpoint mail participant every six month , follow-up telephone call make non-responders . Study endpoint confirm review medical record , interview next-of-kin , autopsy report , available .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Death</mesh_term>
	<mesh_term>Death , Sudden , Cardiac</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<mesh_term>Ventricular Dysfunction , Left</mesh_term>
	<criteria>Inclusion Criteria 1 . Evidence Coronary Artery Disease ( CAD ) document prior Myocardial Infarction . 2 . LVEF &gt; 35 % current standard evaluation technique ( e.g. , ) echocardiogram , MUGA , angiography ) . 2.1 . Patients LVEF 3035 % NYHA Class I heart failure history ventricular tachyarrhythmias , inducible ventricular tachycardia electrophysiological ( EP ) test enrol . 3 . If document prior MI present , evidence mildmoderate systolic Left Ventricular Dysfunction EF &gt; 35 â‰¤50 % measure current standard screening technique ( e.g. , echocardiogram , MUGA , angiography ) must present . 4 . Patients age 18 year 1 . CAD define evidence one follow two ( 2 ) criterion : Significant stenosis major epicardial vessel ( &gt; 50 % proximal 70 % distal ) coronary angiography Prior revascularization ( percutaneous coronary intervention coronary artery bypass surgery ) 2 . MI document follow way : From MI hospitalization : Detection rise fall cardiac biomarkers &gt; 99th percentile lab ( e.g. , CPK elevation Troponin least &gt; two time upper limit normal ) together myocardial ischemia least one following : Symptoms Ischemia ECG change indicative new ischemia ( new STT change new LBBB ) Development pathological Q wave Imaging evidence new loss viable myocardium new regional wall motion abnormality If report MI hospitalization available , prior MI meet either follow : Development pathological Q wave Imaging evidence region loss viable myocardium thin fails contract , absence nonischaemic cause Exclusion Criteria 1 . History cardiac arrest spontaneous inducible sustain VT ( 15 beat rate 120 BPM great occurrence cardiac arrest spontaneous VT set acute MI consider exclusion ) . 2 . Unexplained syncope 3 . Current plan implantable cardiac defibrillator ( ICD ) 4 . Any condition cardiac disease , investigator 's judgment , would seriously limit life expectancy ( poor survival ) 5 . Metastatic cancer 6 . Marked valvular heart disease require surgical intervention 7 . Current plan cardiac , renal liver transplant 8 . Current alcohol drug abuse 9 . Unwilling unable provide inform consent 10 . LVEF &lt; 35 % Class IIIV CHF LVEF &lt; 30 % 11 . Participation clinical trial active treatment arm testing agent and/or intervention know antiarrhythmic property</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Sudden Cardiac Death</keyword>
	<keyword>Myocardial Infarction</keyword>
	<keyword>Percutaneous coronary intervention</keyword>
	<keyword>Implantable Cardiac Defibrillator</keyword>
</DOC>